OrthoPediatrics (NASDAQ:KIDS) Earns “Buy” Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of OrthoPediatrics (NASDAQ:KIDSFree Report) in a research report sent to investors on Friday,Benzinga reports. The brokerage currently has a $42.00 price target on the stock.

A number of other brokerages have also issued reports on KIDS. Truist Financial cut their price target on OrthoPediatrics from $34.00 to $28.00 and set a “hold” rating for the company in a research note on Monday, October 14th. JMP Securities restated a “market outperform” rating and issued a $50.00 price target on shares of OrthoPediatrics in a research report on Friday, September 13th.

Get Our Latest Report on OrthoPediatrics

OrthoPediatrics Price Performance

Shares of KIDS traded down $1.77 during mid-day trading on Friday, reaching $25.72. The stock had a trading volume of 367,372 shares, compared to its average volume of 135,689. The business has a fifty day moving average of $27.76 and a 200 day moving average of $29.81. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.96 and a current ratio of 4.90. The firm has a market cap of $622.78 million, a price-to-earnings ratio of -20.91 and a beta of 1.16. OrthoPediatrics has a 12 month low of $24.02 and a 12 month high of $36.23.

Insiders Place Their Bets

In related news, General Counsel Daniel J. Gerritzen sold 10,000 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $29.30, for a total transaction of $293,000.00. Following the sale, the general counsel now owns 77,304 shares in the company, valued at approximately $2,265,007.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 31.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of KIDS. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in OrthoPediatrics in the third quarter worth $295,000. Quest Partners LLC grew its holdings in shares of OrthoPediatrics by 924.4% in the third quarter. Quest Partners LLC now owns 11,986 shares of the company’s stock worth $325,000 after purchasing an additional 10,816 shares during the last quarter. Mutual of America Capital Management LLC increased its stake in OrthoPediatrics by 195.1% in the 3rd quarter. Mutual of America Capital Management LLC now owns 107,609 shares of the company’s stock worth $2,917,000 after buying an additional 71,146 shares during the period. Harbor Capital Advisors Inc. lifted its holdings in OrthoPediatrics by 268.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 246,860 shares of the company’s stock valued at $6,692,000 after buying an additional 179,803 shares in the last quarter. Finally, Conestoga Capital Advisors LLC boosted its position in OrthoPediatrics by 11.1% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 53,853 shares of the company’s stock valued at $1,460,000 after buying an additional 5,380 shares during the period. Hedge funds and other institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

(Get Free Report)

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

Further Reading

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.